Skip to content

Ketamine: all studies

Page 262 of 449: studies 2,611 to 2,620 of 4,486, newest first. Back to the ketamine overview

Research

Role of 5-HT1A Receptor Stimulation in the Medial Prefrontal Cortex in the Sustained Antidepressant Effects of Ketamine

The International Journal of Neuropsychopharmacology December 22, 2017 K. Fukumoto, M. Iijima, Takeo Funakoshi et al.

Abstract Background We previously reported that serotonergic transmission plays an important role in antidepressant effects of ketamine. However, detailed mechanisms have not been elucidated. Among the serotonin receptor subtypes, the serotonin1A receptor in the medial prefrontal cortex has an important role in depression. Here, we investigated the role of the medial prefrontal cortex...

Effects of short term low dose melatonin and ketamine on depressive behavior and BDNF expression in rats with chronic stress depression

Zhonghua xingwei yixue yu naokexue zazhi December 20, 2017 Haonan Li, Hongwei Sun, Yanyu Wang et al.

Objective To evaluate the antidepressant action of melatonin in stress model of depression and the effects of the melatonin on depressive-like behavior. Methods Forty male Wistar rats were randomly divided into four groups(n=10): controls group (CON), chronic unpredictable mild stress group(CUS), chronic unpredictable mild stress group + melatonin group(CUS+ MT) and chronic unpredictable mild...

DOI: 10.3760/cma.j.issn.1674-6554.2017.12.003 (opens in new tab) Behavioural despair test Melatonin Chronic stress Endocrinology +5

Possible role of the gut microbiota–brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model

Translational Psychiatry December 15, 2017 Chun Yang, Youge Qu, Yuko Fujita et al. 231 citations

Accumulating evidence suggests that the gut microbiota-brain axis plays a role in the pathogenesis of depression, thereby contributing to the antidepressant actions of certain compounds. (R)-ketamine has a greater potency and longer-lasting antidepressant effects than (S)-ketamine. Here, we investigated whether the gut microbiota plays a role in the antidepressant effects of these two ketamine...

Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial

American Journal of Psychiatry December 5, 2017 Michael F Grunebaum, Hanga C Galfalvy, Tse-Hwei Choo et al. 428 citations

Objective Pharmacotherapy to rapidly relieve suicidal ideation in depression may reduce suicide risk. Rapid reduction in suicidal thoughts after ketamine treatment has mostly been studied in patients with low levels of suicidal ideation. Method This randomized clinical trial tested the effect of adjunctive sub-anesthetic intravenous ketamine on clinically significant suicidal ideation in major...

Effects of sodium nitroprusside in the prevention of schizophrenia-like symptoms induced by ketamine – A translational double-blind study

December 1, 2017 Tatiana M N Rezende, J. P. Maia-De-Oliveira, Ludmyla Kandratavicius et al.

Background: Recent evidence has shown improvements in schizophrenia symptoms after the infusion of sodium nitroprusside (SNP), a nitric oxide (NO) donor. In the rat model of schizophrenia using ketamine injection, pretreatment with SNP seems to prevent behavioral changes associated with positive symptoms for up to one week. Objective: We investigated whether SNP would have preventative effects...

Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression.

Neuropsychopharmacology December 2017 Tung-Ping Su, Mu-Hong Chen, Cheng-Ta Li et al.

The antidepressant effects of ketamine are thought to depend on brain-derived neurotrophic factor (BDNF) genotype and dose. The purpose of this study was to characterize the dose-related antidepressant effects of ketamine in patients with treatment-resistant depression drawn from a Chinese population predominately possessing lower activity BDNF genotypes (Val/Met, Met/Met). We conducted a...

Ketamine and pharmacological imaging: use of functional magnetic resonance imaging to evaluate mechanisms of action.

Behavioural Pharmacology December 2017 Eric A Maltbie, Gopinath S Kaundinya, Leonard L. Howell

Ketamine has been used as a pharmacological model for schizophrenia as subanesthetic infusions have been shown to produce temporary schizophrenia-like symptoms in healthy humans. More recently, ketamine has emerged as a potential treatment for multiple psychiatric disorders, including treatment-resistant depression and suicidal ideation. However, the mechanisms underlying both the...

Depression in chronic ketamine users: Sex differences and neural bases.

Psychiatry Research Neuroimaging November 30, 2017 Chiang‐Shan R. Li, Sheng Zhang, Chia-Chun Hung et al.

Chronic ketamine use leads to cognitive and affective deficits including depression. Here, we examined sex differences and neural bases of depression in chronic ketamine users. Compared to non-drug using healthy controls (HC), ketamine-using females but not males showed increased depression score as assessed by the Center of Epidemiological Studies Depression Scale (CES-D). We evaluated resting...

TrkB dependent adult hippocampal progenitor differentiation mediates sustained ketamine antidepressant response

Nature Communications November 21, 2017 Zhenzhong Ma, Tong Zang, Shari G. Birnbaum et al.

Adult neurogenesis persists in the rodent dentate gyrus and is stimulated by chronic treatment with conventional antidepressants through BDNF/TrkB signaling. Ketamine in low doses produces both rapid and sustained antidepressant effects in patients. Previous studies have shed light on post-transcriptional synaptic NMDAR mediated mechanisms underlying the acute effect, but how ketamine acts at...